Floatz logo

68ganota-anti-mmr-vhh2

Sarcoidosis

Universitair Ziekenhuis BrusselradiopharmaceuticalPhase 2Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Sarcoidosis cohort.

Asset / SponsorPhaseRating
BARDOXOLONE METHYL ESTER
Biogen
Phase 2B

Same molecule, other indications

68ganota-anti-mmr-vhh2 is also rated in:

cancerDormant
C
Indicative ·
36 / 100
View asset →
carotid stenosisDormant
C
Indicative ·
36 / 100
View asset →
head and neck cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →